In today’s briefing:
- Pre-IPO Mirxes Holding (PHIP Updates) – Some Points Worth the Attention
- SGX Group (SGX SP): Likely More Listings. Triggered by Trade Tensions, Tax Perks
Pre-IPO Mirxes Holding (PHIP Updates) – Some Points Worth the Attention
- GASTROClear’s clinical application may be limited by doctors’ lack of sufficient trust/recognition. GASTROClear could mainly be commercialized in the non-clinical market in China first. However, the competition is more intense.
- The dual pressure of lack of medical insurance reimbursement and higher pricing may lead to lower-than-expected market penetration.It’s not easy for Mirxes’ revenue to return to the level of 2021.
- Short-Term valuation depends on market sentiment, but in long term, it still depends on the commercialization performance and the improvement of cash flow. The IPO pricing is expensive.
SGX Group (SGX SP): Likely More Listings. Triggered by Trade Tensions, Tax Perks
- Reported surge in listing interest on SGX (SGX SP) driven by escalating U.S.- China trade tensions and associated geopolitical uncertainties.
- Singapore’s proactive policy toolkit announced in February 2025 offer issuers both cost savings and regulatory certainty and could play a role in attracting more companies to list in Singapore.
- An uptick in listings on the Singapore Exchange (SGX) can set off a virtuous cycle, strengthen valuation multiples and lead to upward revisions to 2026 earnings forecasts.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
